Regorafenib: from clinical research to clinical practice
Regorafenib is a new multiple tyrosine kinase inhibitor with anti-cancer and anti-angiogenic activity which application has been recently approved by the Russian Federation in patients with colon cancer and gastrointestinal tumors. The approval of application of regorafenib for the treatment of pati...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IP Habib O.N.
2017-09-01
|
| Series: | Современная онкология |
| Subjects: | |
| Online Access: | https://modernonco.orscience.ru/1815-1434/article/viewFile/27137/pdf |
| _version_ | 1819106669019267072 |
|---|---|
| author | M Yu Fedyanin A A Tryakin |
| author_facet | M Yu Fedyanin A A Tryakin |
| author_sort | M Yu Fedyanin |
| collection | DOAJ |
| description | Regorafenib is a new multiple tyrosine kinase inhibitor with anti-cancer and anti-angiogenic activity which application has been recently approved by the Russian Federation in patients with colon cancer and gastrointestinal tumors. The approval of application of regorafenib for the treatment of patients with hepatocellular carcinoma is expected. This review discusses the main clinical studies of the drug: the steps of appointment, the prevention and the treatment of the complications using new tyrosine kinase inhibitor; the views of the Russian and foreign experts who should help chemotherapist in the clinical practice. |
| first_indexed | 2024-12-22T02:41:49Z |
| format | Article |
| id | doaj.art-fe20a82fbfa74b63a6bfe38266be98ae |
| institution | Directory Open Access Journal |
| issn | 1815-1434 1815-1442 |
| language | Russian |
| last_indexed | 2024-12-22T02:41:49Z |
| publishDate | 2017-09-01 |
| publisher | IP Habib O.N. |
| record_format | Article |
| series | Современная онкология |
| spelling | doaj.art-fe20a82fbfa74b63a6bfe38266be98ae2022-12-21T18:41:38ZrusIP Habib O.N.Современная онкология1815-14341815-14422017-09-01193192424357Regorafenib: from clinical research to clinical practiceM Yu Fedyanin0A A Tryakin1N.N.Blokhin National Medical Reseach Center of Oncology of the Ministry of Health of the Russian Federation.N.N.Blokhin National Medical Reseach Center of Oncology of the Ministry of Health of the Russian Federation.Regorafenib is a new multiple tyrosine kinase inhibitor with anti-cancer and anti-angiogenic activity which application has been recently approved by the Russian Federation in patients with colon cancer and gastrointestinal tumors. The approval of application of regorafenib for the treatment of patients with hepatocellular carcinoma is expected. This review discusses the main clinical studies of the drug: the steps of appointment, the prevention and the treatment of the complications using new tyrosine kinase inhibitor; the views of the Russian and foreign experts who should help chemotherapist in the clinical practice.https://modernonco.orscience.ru/1815-1434/article/viewFile/27137/pdfregorafenibcolon cancergastrointestinal tumorhepatocellular carcinoma |
| spellingShingle | M Yu Fedyanin A A Tryakin Regorafenib: from clinical research to clinical practice Современная онкология regorafenib colon cancer gastrointestinal tumor hepatocellular carcinoma |
| title | Regorafenib: from clinical research to clinical practice |
| title_full | Regorafenib: from clinical research to clinical practice |
| title_fullStr | Regorafenib: from clinical research to clinical practice |
| title_full_unstemmed | Regorafenib: from clinical research to clinical practice |
| title_short | Regorafenib: from clinical research to clinical practice |
| title_sort | regorafenib from clinical research to clinical practice |
| topic | regorafenib colon cancer gastrointestinal tumor hepatocellular carcinoma |
| url | https://modernonco.orscience.ru/1815-1434/article/viewFile/27137/pdf |
| work_keys_str_mv | AT myufedyanin regorafenibfromclinicalresearchtoclinicalpractice AT aatryakin regorafenibfromclinicalresearchtoclinicalpractice |